Data in Biotech
Data in Biotech brings data leaders from across biotech, pharma, and life sciences into honest conversations about how their organizations actually use data. Host Ross Katz talks with directors, VPs, and heads of data about the real challenges: building data cultures in regulated environments, scaling analytics teams, and turning experimental data into business decisions. Over 58 episodes, the show has featured leaders from companies like Lyell Immunopharma, Recursion, and Tempus.
Hosted by Ross Katz
Show Details
Sample an episode
Foundation models in biomedical AI with Kevin Brown
Episodes
Page 1 of 4
Synthesizable by Design: AI for Small Molecule Drug Discovery
with Paul Finn, Chief Scientific Officer at Oxford Drug Design
Oxford Drug Design's Paul Finn on synthesizability as a first-class constraint, why chemistry is harder for AI than biology, and what to ask AI vendors.
From Tissue to Mechanism to Decision: AI for Computational Oncology
with Arvind Rao, Professor of Computational Medicine and Bioinformatics at University of Michigan
Arvind Rao of Michigan on SPIFEE and the tumor microenvironment, multimodal AI from tissue to drug target, and why clinical AI needs credentialing.
Cavities in the Data: Building FDA-Cleared AI for Dental Imaging
with Sadegh Salehi, Director of Research and Principal Scientist at Overjet
Overjet's Sadegh Salehi on subgroup evaluation, sensor shortcuts in training data, and the FDA's Predetermined Change Control Plan for medical AI.
Data as a Moat: Biotech's Most Valuable Asset Lives on a Hard Drive
with Jesse Johnson, Founder at Merelogic
Jesse Johnson of Merelogic on why bio foundation models flipped the value equation for biotech experimental data, and what labs need to do to capture it.
The Patient Is Not a Document: Foundation Models for Biomedical AI
with Kevin Brown, Founder and CEO at Standard Model Biomedicine
Kevin Brown of Standard BioModel on building multimodal foundation models that map imaging, pathology, genomics, and EHR data into a shared latent space.
Physics, Free Energy, and Computational Drug Discovery
with Robert Abel, Chief Scientific Officer, Platform at Schrödinger
Robert Abel of Schrödinger on why ML alone fails in 10^60 chemical space and how physics-based simulation reaches near-experimental accuracy.
AI in Biotech: Separating Hype from Reality
with Ben Locwin, Vice President at Reliant Life Sciences
Ben Locwin of Reliant Life Sciences on why most biotech AI claims fall short, AlphaFold as the gold standard, and why data quality beats algorithmic complexity.
3D Printing Therapeutics at Scale with Aprecia
with Kyle Smith, President & COO at Aprecia Pharmaceuticals
Kyle Smith and Jacob Mayer of Aprecia explain how binder jetting and in-cavity 3D printing enable real-time tablet data, digital twins, and personalized pharma.
Success-Driven Drug Discovery with OpenBench CEO James Yoder
with James Yoder, Founder & CEO at OpenBench
James Yoder of OpenBench explains a success-driven model for early-stage drug discovery using computational screening and AI-powered hit scoring.
Brant Peterson on Valo Health's Patient-First Drug Discovery
with Brant Peterson, Vice President & Fellow, Data Science at Valo Health
Brant Peterson of Valo Health discusses how patient data, genetics, and causal reasoning shape drug discovery decisions before a molecule reaches the clinic.
Inside Dash Bio's Productized CRO Model with Ander Tallet
with Ander Tallet, Co-founder and COO at Dash Bio
Ander Tallet of Dash Bio explains how automation, transparency, and productization are reimagining conventional CRO approaches in biotech.
From Discovery to Delivery: AI's Impact on Nanomedicine
with Mitra Mosharraf, Chief Scientific Officer at HTD Biosystems
Mitra Mosharraf of HTD Biosystems discusses how AI and machine learning are transforming nanomedicine discovery, formulation, and clinical delivery.
Jaidev Chakka on Building the Future of Bioprinted Medicine
with Jaidev Chakka, Principal Scientist at University of Mississippi School of Pharmacy
Jaidev Chakka explores how 3D bioprinting and AI are enabling personalized drug manufacturing, custom bone scaffolds, and organoid-based testing.
How Veloxity Accelerates Critical Drug Decisions
with Callie Celichowski, Business Development at Veloxity Labs & Isa Kupke, Scientist II at Veloxity Labs
Isa Kupke of Veloxity Labs discusses how mass spectrometry and cloud infrastructure drive rapid bioanalytical insights for drug development.
Revolutionizing Bioanalysis with High-Resolution Mass Spec
with Eshani Galermo, Staff Scientist at SCIEX
Eshani Galermo of SCIEX discusses innovations in high-resolution mass spectrometry for pharmaceutical and biopharmaceutical bioanalysis applications.
Mastering Solubility and Stability with Serán BioScience
with Wesley Tatum, Principal Engineer at Serán BioScience
Wesley Tatum of Serán BioScience discusses data-driven formulation of low-solubility drugs, amorphous solid dispersions, and AI in pharmaceutical development.
Applying ML/AI to Drug Development with Anil Kane
with Dr. Anil Kane, Executive Director and Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific
Dr. Anil Kane of Thermo Fisher Scientific discusses how AI, machine learning, and digital tools are reshaping drug development and manufacturing efficiency.
Streamlining Bioanalytical Workflows with Watson LIMS
with John Liberty, Senior Bioanalysis Technical Sales Consultant at Thermo Fisher Scientific
John Liberty of Thermo Fisher Scientific explains how Watson LIMS supports regulated bioanalysis workflows, lab automation, and digital system unification.
Scaling AI Infra in Biotech with Saturn Cloud and Nebius
with Hugo Shi, CTO and Founder at Saturn Cloud & Ilya Burkov, Global Head of Healthcare and Life Science Growth at Nebius
Hugo Shi of Saturn Cloud discusses how specialized AI infrastructure solves compliance, scale, and security challenges for modern biotech teams.
Co-Folding and Federated Learning with Apheris
with Robin Roehm, CEO and Co-Founder at Apheris
Robin Roehm of Apheris explains how federated learning enables secure cross-company AI collaboration in pharma without moving sensitive data.
Need help with biotech data?
CorrDyn works with life sciences companies to build data infrastructure that accelerates research and operations. The same expertise behind these conversations.
Book an intro callGuest Companies
Data leaders from across the life sciences ecosystem.